TheraRadar
← Back
Data updated: Jun 28, 2026

SUNSHINE LAKE PHARMA CO LTD

Biotech
Infectious DiseaseOncologyRespiratory Execution: Good

SUNSHINE LAKE PHARMA CO LTD is a biotechnology company focused on Infectious Disease, Oncology, Respiratory.

2026
Since
2
Drugs
-
Trials
1
New Drugs (2yr)

SUNSHINE LAKE PHARMA CO LTD at a Glance

  • Fast trial execution (12 months median completion)

SUNSHINE LAKE PHARMA CO LTD's Key Drugs

SUNSHINE LAKE PHARMA CO LTD's core commercial portfolio centers on LANGLARA, spanning Infectious Disease and Oncology — its most strategically important drugs approved in the last 15 years.

LANGLARA
Approved 2026

SUNSHINE LAKE PHARMA CO LTD's Recent FDA Approvals

SUNSHINE LAKE PHARMA CO LTD secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

LANGLARA BLA
2026-04-29
insulin glargine-aldy
1 INDICATIONS AND USAGE LANGLARA is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. LANGLARA is a long-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ( 1 ) Limitations of Use Not recommended for the treatment of diabetic ketoacidosis. ( 1 ) Limitations of Use LANGLARA is not recommended for the treatment of diabetic ketoacidosis.

SUNSHINE LAKE PHARMA CO LTD's Therapeutic Areas

SUNSHINE LAKE PHARMA CO LTD's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 39%
0 drugs Phase 3: 1 Phase 2: 5 Phase 1: 15
Oncology 27%
0 drugs Phase 3: 2 Phase 1: 12
Respiratory 19%
0 drugs Phase 3: 1 Phase 2: 2 Phase 1: 6
Metabolic 14%
0 drugs Phase 3: 1 Phase 1: 6
Neurology 1%
0 drugs Phase 1: 1

SUNSHINE LAKE PHARMA CO LTD's Top Competitors

SUNSHINE LAKE PHARMA CO LTD's closest competitors by therapeutic-area and drug-target overlap include Merck, GSK, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Merck big-pharma
Oncology, Infectious Disease, Metabolic, Respiratory
GSK big-pharma
Respiratory, Infectious Disease, Oncology, Metabolic
Pfizer big-pharma
Oncology, Infectious Disease, Neurology
GE HEALTHCARE specialty
Neurology, Infectious Disease, Oncology, Respiratory
Baxter specialty
Infectious Disease, Oncology, Metabolic

SUNSHINE LAKE PHARMA CO LTD Pipeline Snapshot

SUNSHINE LAKE PHARMA CO LTD has 52 active clinical programs from ClinicalTrials.gov — 5 Phase 3, 7 Phase 2 and 40 Phase 1.

5
Phase 3
7
Phase 2
40
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • LANGLARA leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Infectious Disease pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 2/5 completed
  • • Speed: 12 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges